Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/25/2022 | $20.00 → $16.00 | Outperform | Credit Suisse |
| 1/25/2022 | $20.00 → $6.20 | Buy → Hold | Stifel |
| 1/25/2022 | $33.00 → $8.00 | Market Outperform | JMP Securities |
| 11/9/2021 | $20.00 | Hold → Buy | Stifel |
| 10/12/2021 | $20.00 | Outperform | Credit Suisse |
| 10/4/2021 | $20.00 | Buy | Mizuho |
| 9/21/2021 | $33.00 | Market Outperform | JMP Securities |
| 9/20/2021 | $20.00 | Hold | Stifel |
EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)
Credit Suisse reiterated coverage of eFFECTOR Therapeutics with a rating of Outperform and set a new price target of $16.00 from $20.00 previously
Stifel downgraded eFFECTOR Therapeutics from Buy to Hold and set a new price target of $6.20 from $20.00 previously
JMP Securities reiterated coverage of eFFECTOR Therapeutics with a rating of Market Outperform and set a new price target of $8.00 from $33.00 previously
SC 13D/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
SC 13G/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
SC 13G/A - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a d
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board's Audit Committee. Concurrent with Ms. Loewy's appointment, current Board member John Smither has resigned from the Board. "We are tremendously fortunate to welcome Caroline given her extensive experience as an executive and board member at multiple biopharmaceutical companies," remarked Steve Worland, Ph.D., president and chief executive office
- Key executive appointments: Douglas Warner, M.D., as CMO & Mayank Gandhi, M.D., as CBO – - Cohort treating ER+ breast cancer with combination of zotatifin, fulvestrant and abemaciclib has been expanded from 7 patients to 18 patients - - Initiated dosing and completed enrollment in second cohort of Phase 1b clinical trial of zotatifin for the treatment of COVID-19 - SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a d
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer and low grade serous ovarian cancer at the Dana-Farber Cancer Institute (DFCI) under the direction of Panagiotis Konstantinopoulos, M.D., Ph.D., Director of Translational Research and attending oncologist in the Division of Gynecologic Oncology at
Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. "We had a productive first quarter marked by continued progress in the zotatifin program, including successful completion of the
Partial responses observed in 5 of 19 (26%) evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib (ZFA triplet) in heavily pretreated populationPartial response observed in 1 of 3 (33%) patients treated with zotatifin 0.1 mg/kg combined with fulvestrant (ZF doublet)Both combinations were generally well tolerated with large majority of adverse events Grade 1 or 2Company will host a virtual investor call on June 4, 2023, to discuss the data and clinical progress SOLANA BEACH and REDWOOD CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("
Updated data from two fully enrolled Phase 2 expansion cohorts testing zotatifin-based combinations in estrogen receptor-positive (ER+) Metastatic Breast Cancer to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 on June 4, 2023 Company will host conference call to discuss results and further development of zotatifin during ASCO Annual Meeting 2023 Zotatifin is being evaluated in patients with ER+, human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a pre-operative setting through clinical collaboration with Jennifer Caswell-Jin, M.D., Assistant Professor of Medicine at Stanford Medicine SOLANA BEACH and REDWOOD CITY, Calif.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced a poster highlighting results from Phase 2 expansion cohorts of a Phase 1/2 dose escalation and expansion trial with zotatifin in patients with ER+ Metastatic Breast Cancer has been selected for presentation at the American Society of Clinical Oncology ("ASCO") 2023 Annual Meeting. Following the presentation, eFFECTOR will host a conference call to discuss the data. The ASCO website indicates that abstracts will be released on May 25, 2023
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)
4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)